ライフサイエンスコーパス: biopharmaceutical

1 edefining, rebranding and co-opting what is 'biopharmaceutical'.

2 DA-bound concentrations of all non-IgG-based biopharmaceuticals.

3 more common route for the administration of biopharmaceuticals.

4 n of disease states and the manufacturing of biopharmaceuticals.

5 within the charge variant profile of complex biopharmaceuticals.

6 es are currently the most important class of biopharmaceuticals.

7 lonal antibodies (mAbs) are a major class of biopharmaceuticals.

8 ractive for improving the serum half-life of biopharmaceuticals.

9 ning the therapeutic outcomes of SC injected biopharmaceuticals.

10 ng others, with diseases and the efficacy of biopharmaceuticals.

11 ing of mAb quality in process development of biopharmaceuticals.

12 xpression cell line during the production of biopharmaceuticals.

13 ased quality and affordability of high-value biopharmaceuticals.

14 y for FcRn, HSA is versatile as a carrier of biopharmaceuticals.

15 for analysis of serum half-life of HSA-based biopharmaceuticals.

16 red to promote binding and recovery of these biopharmaceuticals.

17 y be used for quality control of recombinant biopharmaceuticals.

18 n proteins, are a novel and growing class of biopharmaceuticals.

19 is critically important to the production of biopharmaceuticals.

20 ges, limiting their effective application as biopharmaceuticals.

21 t monoclonal IgG1 antibody, a major class of biopharmaceuticals.

22 detected modifications of well-characterized biopharmaceuticals.

23 monitoring conformational changes in protein biopharmaceuticals.

24 onoclonal antibodies are a major subclass of biopharmaceuticals.

25 stems for production of vaccine antigens and biopharmaceuticals.

26 ation has turned proteins into important new biopharmaceuticals.

27 cturing platform for the production of human biopharmaceuticals.

28 at engineered antibodies have come of age as biopharmaceuticals.

29 express high levels of vaccine antigens and biopharmaceuticals.

30 e phases for LC-MS-based characterization of biopharmaceuticals.

31 (ADCs) have become a major class of oncology biopharmaceuticals.

32 nd promote the applications of both MOFs and biopharmaceuticals.

33 ing crop productivity, and the production of biopharmaceuticals.

34 erization of original and biosimilar protein biopharmaceuticals.

35 quality from intact mass analysis of protein biopharmaceuticals.

36 s a rich source of known and potentially new biopharmaceuticals.

37 evading immune surveillance in the field of biopharmaceuticals.

38 ntation, and other fields is among the major biopharmaceutical advances of the 20th century.

39 on proteins (immunocytokines) are innovative biopharmaceutical agents, which are being considered for

40 able addition to the experimental toolbox of biopharmaceutical analysis.

41 as the potential to be widely implemented in biopharmaceutical analytical laboratories.

42 is gaining high recent interest in both the biopharmaceutical and biomedical fields.

43 ocedure in view of the production of SLM for biopharmaceutical and biotech protocols.

44 Biopharmaceutical and biotechnology companies and regula

45 development of novel screening platforms for biopharmaceutical and environmental applications.

46 protein stability is essential not only for biopharmaceutical and food manufacturing but also for th

47 In addition to biopharmaceutical and industrial applications, stable pr

48 rotein acidostability is a common problem in biopharmaceutical and other industries.

49 Biopharmaceutical and regulatory agencies rely heavily o

50 (ELISA) is a widely used tool for analyzing biopharmaceutical and vaccine products.

51 trion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with

52 ising vehicles for intracellular delivery of biopharmaceuticals and could increase the utility of pol

53 till an emergent tool for quality control of biopharmaceuticals and for establishing dynamic similari

54 eomics, during development and production of biopharmaceuticals and for the clinical analysis of glyc

55 pportunities for the optimization of protein biopharmaceuticals and for the development of cell-perme

56 mon chemical degradation pathway observed in biopharmaceuticals and is particularly prevalent in synt

57 a catalyst for the development of vaccines, biopharmaceuticals and small molecule therapeutics.

58 Biopharmaceuticals and small-molecule drugs have differe

59 are important to both the supply of marketed biopharmaceuticals and the pipelines of novel therapeuti

60 es may be very useful for quality control of biopharmaceuticals and their biosimilars.

61 ation and absolute quantification of protein biopharmaceuticals and their product-related impurities,

62 sialylated O-glycans most commonly found on biopharmaceuticals) and bovine submaxillary gland mucin

63 cterization and quality control step for any biopharmaceutical, and this is usually measured by fluor

64 ationship in the context of physicochemical, biopharmaceutical, and toxicological profiling.

65 trating their potential for biocatalysis and biopharmaceutical applications.

66 ational design methods for biotechnology and biopharmaceutical applications.

67 vel has a great potential for biomedical and biopharmaceutical applications.

68 -specific reactive immunization, a potential biopharmaceutical approach to glycation-related patholog

69 Protein biopharmaceuticals are an important and growing area of

70 Protein-based biopharmaceuticals are becoming increasingly widely used

71 Monoclonal antibodies and recombinant DNA biopharmaceuticals are derived from relatively homogeneo

72 As many biopharmaceuticals are glycosylated in order to be funct

73 Protein biopharmaceuticals are highly successful, but their util

74 Biopharmaceuticals are making increasing impact on medic

75 As more protein biopharmaceuticals are produced using mammalian cell cul

76 nal antibodies, the fastest growing class of biopharmaceuticals, as well as membrane-associated and c

77 horesis and cIEF should be considered during biopharmaceutical assay development.

78 C to resolve hydrophilic variants of protein biopharmaceuticals at the middle-up level of analysis, i

79 tforms which will have significant impact in biopharmaceutical-based therapeutics.

80 Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small siz

81 t and quality control of modern glycosylated biopharmaceuticals, but also in clinical biomarker disco

82 modular approach to append functionality to biopharmaceuticals by noncovalent modification with othe

83 s) are fundamental to the variability of the biopharmaceutical characteristics of drugs and to underl

84 Difficult biopharmaceutical characteristics of oligonucleotides, s

85 eotide using a brush polymer can improve its biopharmaceutical characteristics, including enzymatic s

86 romatography-mass spectrometry (LC-MS)-based biopharmaceutical characterization to enhance reversed-p

87 areas of structural biology, biophysics, and biopharmaceutical characterization.

88 d widely applied LC-MS techniques in protein biopharmaceutical characterization.

89 c antibodies and biosimilars, an appropriate biopharmaceutical CMC control strategy that connects cri

90 biological environments and increasingly in biopharmaceutical co-formulations.

91 A key challenge for the academic and biopharmaceutical communities is the rapid and scalable

92 s medicines, have long provided value to the biopharmaceutical community as models of success, often

93 o further increase the utility of NMR to the biopharmaceutical community, harmonized criteria for dec

94 ed stocks, we track the performance of 1,066 biopharmaceutical companies from 1930 to 2015-the most c

95 A majority of the largest biopharmaceutical companies have announced strategic par

96 The performance of all biopharmaceutical companies is subject not only to facto

97 unding the risk and reward of investments in biopharmaceutical companies poses a challenge to those i

98 in which it established collaborations with biopharmaceutical companies to support early-stage effor

99 Support from major biopharmaceutical companies, development of hydroponic p

100 ed and used by many other parties, including biopharmaceutical companies, payors, clinical researcher

101 xperience as a portfolio manager in a larger biopharmaceutical company and the skills from academic r

102 be highly specific in the presence of common biopharmaceutical components and could thus serve as an

103 creasingly used for the capture of different biopharmaceutical compounds within complex biological mi

104 particularly critical as the development of biopharmaceuticals continuously gains significance.

105 e system models environmental changes that a biopharmaceutical could experience as it transitions fro

106 precisely controlled release of SC injected biopharmaceuticals could be achieved.

107 LC-MS based analysis of protein biopharmaceuticals could benefit from improved data qual

108 Residual host cell proteins (HCPs) in biopharmaceuticals derived from recombinant DNA technolo

109 6 orders of magnitude less abundant than the biopharmaceutical-derived peptides.

110 a convenient quality examination tool during biopharmaceutical development and manufacturing processe

111 A major limitation in biopharmaceutical development is selectively targeting d

112 ted technologies even at early stages of the biopharmaceutical development platform, such as in devel

113 otential to benefit and accelerate the early biopharmaceutical development process, particularly by e

114 trifugation (SV-AUC) is routinely applied in biopharmaceutical development to measure levels of prote

115 represent the dominant production hosts for biopharmaceutical development, yet the physiology of the

116 t quality attribute that is monitored during biopharmaceutical development.

117 EGs), up to 40 kDa, typical of those used in biopharmaceutical development.

118 apeutic) proteins, which are widely used for biopharmaceutical development.

119 ant targets for fundamental research and for biopharmaceutical development.

120 nt for biomolecular research, diagnosis, and biopharmaceutical development.

121 However, many antibodies and other biopharmaceuticals display inferior biophysical properti

122 Anticalins are a novel class of biopharmaceuticals, displaying highly desirable attribut

123 ologies that are increasingly being used for biopharmaceutical drug discovery.

124 no association between drug lipophilicity or Biopharmaceutical Drug Disposition Classification System

125 is a critical attribute of any protein-based biopharmaceutical drug due to a protein's inherent tende

126 he antithrombin III (AT)-binding site in the biopharmaceutical drug heparin.

127 In recent years, biopharmaceutical drug products have become hugely succe

128 ng remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each

129 ikelihood for such defects is heightened for biopharmaceuticals due to their complexity, which makes

130 the analytical characterization of proteins biopharmaceuticals, due to its inherent compatibility wi

131 Biopharmaceuticals, e.g. liquid-formulated vaccines with

132 can thus screen and evolve 'manufacturable' biopharmaceuticals early in industrial development.

133 for the enhanced characterization of complex biopharmaceuticals, especially those with charge and gly

134 ve colitis (n = 36) treated with 8 different biopharmaceuticals (etanercept, n = 84; infliximab, n =

135 human erythropoietin (rhEPO) is an important biopharmaceutical for which glycosylation is a critical

136 n studies of skin-impermeant medications and biopharmaceuticals for clinical applications.

137 le method to examine the potential fate of a biopharmaceutical formulation after its SC injection in

138 d to anticipate the in vivo performance of a biopharmaceutical formulation intended for SC injection.

139 ggregates, including subvisible particles in biopharmaceutical formulations.

140 otein concentration and aggregate content in biopharmaceutical formulations.

141 ool for characterizing protein aggregates in biopharmaceutical formulations.

142 Movement of a biopharmaceutical from the injection chamber to the infi

143 components that may affect the release of a biopharmaceutical from the SC injection site.

144 Along with the recent increase in biopharmaceutical funding in gene therapy, industry part

145 The correct glycosylation of biopharmaceutical glycoproteins and their formulations i

146 e SC tissue when formulating for SC injected biopharmaceuticals has improved the predictability of dr

147 , there is interest in implementing LC-MS in biopharmaceutical HCP profiling alongside conventional E

148 The European consortium ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis

149 thalmology is likely to involve the areas of biopharmaceuticals, implantable materials (e.g. tissue r

150 Heparin is the most widely prescribed biopharmaceutical in production globally.

151 yield bioreactor for the production of human biopharmaceuticals in egg whites using genetic engineeri

152 MS) and (1)H NMR for the glycome analysis of biopharmaceuticals in research, development, and quality

153 They are structurally different from other biopharmaceuticals in size and quaternary structure.

154 gs, the conformational properties of protein biopharmaceuticals in solution are influenced by a varie

155 te, National Institutes of Health, and Eiger Biopharmaceuticals Inc.

156 eta4, ranging from 25 to 100 ng/ml (RegeneRx Biopharmaceuticals Inc., Rockville, MD), for 4 days.

157 apeutic glycoproteins has been emphasized in biopharmaceutical industries because the carbohydrate co

158 altered the nature of the biotechnology and biopharmaceutical industries.

159 ul for high-throughput screening purposes in biopharmaceutical industries.

160 aggregation is a significant problem in the biopharmaceutical industry (protein drug stability) and

161 tal to fulfill the contemporary needs of the biopharmaceutical industry and requirements of national

162 racentrifugation (SV-AUC) has emerged in the biopharmaceutical industry as a technique to detect smal

163 ibody (rMab) drugs is a major concern in the biopharmaceutical industry as it impacts the drugs' many

164 od development will be to the benefit of the biopharmaceutical industry as there is an ever-increasin

165 mass spectrometry can and should play in the biopharmaceutical industry beyond the presently assigned

166 BsAbs) have drawn increasing interest in the biopharmaceutical industry due to their advantage to bin

167 rch efforts in academic institutions and the biopharmaceutical industry have become increasingly tran

168 f therapeutic and endogenous proteins in the biopharmaceutical industry over the past several years,

169 good manufacturing practices (cGMP) based on biopharmaceutical industry standards and summarizes the

170 s, it becomes increasingly important for the biopharmaceutical industry to have tools to characterize

171 ectric focusing (cIEF) is widely used in the biopharmaceutical industry to measure the charge distrib

172 The modern biopharmaceutical industry traces its roots to the dawn

173 In the biopharmaceutical industry, elucidation of the cysteine

174 biosyntheses, once only in the realm of the biopharmaceutical industry, have now been embraced by th

175 r a variety of approaches used widely by the biopharmaceutical industry, involves synonymous substitu

176 Within the biopharmaceutical industry, recombinant plasmid DNA is u

177 duction of biologics, a growing trend in the biopharmaceutical industry, requires a reliable and effi

178 ectrophoresis in biomedical research and the biopharmaceutical industry, the development of data inte

179 For the protein biopharmaceutical industry, therefore, it is important t

180 fluorescence calibration methodology for the biopharmaceutical industry, yielding a value of sensitiv

181 itor other attributes and applied across the biopharmaceutical industry.

182 Biologic drugs are promoting growth in the biopharmaceutical industry.

183 immune system and of vital importance in the biopharmaceutical industry.

184 tic antibodies is of great importance to the biopharmaceutical industry.

185 enteral administration are of concern in the biopharmaceutical industry.

186 ations (PTMs) of recombinant proteins in the biopharmaceutical industry.

187 proteins is of increasing interesting in the biopharmaceutical industry.

188 product release and stability testing in the biopharmaceutical industry.

189 ces governing microbiological testing in the biopharmaceutical industry.

190 of biologics is one of the priorities of the biopharmaceutical industry.

191 es have become a major driving force for the biopharmaceutical industry; therefore, the discovery and

192 Chemical modifications on protein biopharmaceuticals introduce extra variability in additi

193 The manufacture of protein biopharmaceuticals is conducted under current good manuf

194 Enhancing the stability of biopharmaceuticals is essential for their wide applicati

195 on of an expression platform for recombinant biopharmaceuticals is often centered upon suitable produ

196 the first time for in planta quantitation of biopharmaceuticals, is especially useful for insoluble o

197 odies is an area of significant focus in the biopharmaceutical landscape.

198 cal assets in the discovery and selection of biopharmaceutical lead candidates.

199 which is a major concern for developing new biopharmaceutical leads.

200 an orally, both of which suggest substantial biopharmaceutical liabilities.

201 res (Ethicon, NJ), Evicel fibrin glue (Omrix Biopharmaceuticals Ltd, Ramat-Gan, Israel), or Tisseel f

202 nt human erythropoetin (EPO) is an important biopharmaceutical mainly used for the treatment of anemi

203 al to provide enhanced forms of Cannabis for biopharmaceutical manufacture.

204 Viral contamination in biopharmaceutical manufacturing can lead to shortages in

205 Biopharmaceutical manufacturing capacity has moved throu

206 Current biopharmaceutical manufacturing systems are not compatib

207 part of many industrial processes, including biopharmaceutical manufacturing.

208 Oxidation of biopharmaceuticals may affect their bioactivity, serum h

209 Here, a platform approach to biopharmaceutical modification is described that relies

210 bacteria are potential delivery vehicles for biopharmaceutical molecules because they are well-recogn

211 ly monitoring the in vivo deamidation of the biopharmaceutical monoclonal antibody trastuzumab at a c

212 Pulmonary delivery of siRNA-based biopharmaceuticals offers the potential to address multi

213 Biopharmaceutical optimization of the resulting leads cu

214 ajor costs associated with the production of biopharmaceuticals or vaccines in fermentation-based sys

215 ic agents, and the characterization of these biopharmaceuticals poses a significant analytical challe

216 ly intended to address challenges arising in biopharmaceutical practice by promoting improved stabili

217 In biopharmaceutical process development, it is desirable t

218 The potential impact of transcriptomics on biopharmaceutical process technology is also discussed.

219 detection and monitoring of this epitope in biopharmaceuticals produced in recombinant mammalian sys

220 l play an increasing role in next generation biopharmaceutical product characterization like bsAbs, a

221 ing protein aggregation at various stages of biopharmaceutical product design.

222 characterizing conformational changes in the biopharmaceutical product interferon beta-1a (IFN-beta-1

223 ty is also potentially useful for optimizing biopharmaceutical production and manufacturing nanofiber

224 can analysis has become an important part of biopharmaceutical production and quality control.

225 Development of biopharmaceutical production cell lines requires efficie

226 trate this, we de novo-created promoters for biopharmaceutical production in CHO cells that exhibited

227 verse proteins is particularly important for biopharmaceutical production.

228 n the early research and discovery phases of biopharmaceutical production.

229 Biopharmaceutical products (BPs) are widely used to trea

230 omposite mixtures of antibodies representing biopharmaceutical products coexpressed from single cells

231 Characterization of biopharmaceutical products is a challenging task, which

232 e tool for characterization of heterogeneous biopharmaceutical products such as bispecific antibodies

233 pically present at low levels in recombinant biopharmaceutical products, such as therapeutic antibodi

234 ard" for subvisible particle measurements in biopharmaceutical products, the current technology has l

235 sed attention to quality by design (QbD) for biopharmaceutical products, there is a demand for accura

236 ualitative and semiquantitative profiling of biopharmaceutical products.

237 iseases to development of safe and efficient biopharmaceutical products.

238 C to provide guidance for improvement of its biopharmaceutical profile.

239 In vitro biopharmaceutical properties and in vivo oral absorption

240 The modified biopharmaceutical properties of 3 translated into excell

241 ce of the differing acyl groups on these key biopharmaceutical properties, confirming that acyl group

242 Chemical modification to improve biopharmaceutical properties, especially oral absorption

243 ally penetrant molecule which possesses good biopharmaceutical properties, is highly water-soluble, a

244 explore novel TNIK inhibitors with desirable biopharmaceutical properties.

245 er systemic administration due to individual biopharmaceutical properties.

246 ormone-related adverse effects and improving biopharmaceutical properties.

247 potency and unattractive pharmacological and biopharmaceutical properties.

248 g selectivity for JAK3 versus JAK1, and good biopharmaceutical properties.

249 e large dynamic range between high abundance biopharmaceutical proteins and low abundance HCPs.

250 Oral delivery of biopharmaceutical proteins expressed in plant cells shou

251 he simultaneous quantification of the 60-kDa biopharmaceutical proteins recombinant human tumor necro

252 haracterization and quantitative analysis of biopharmaceutical proteoforms.

253 r future molecules during the development of biopharmaceuticals, reducing the need for live subject s

254 ue for the facile preparation and storage of biopharmaceuticals represented by antibodies under ambie

255 ties thus providing valuable information for biopharmaceutical research and development.

256 vity levels realistic to the requirements of biopharmaceutical research and development.

257 e quality and quantity of pharmaceutical and biopharmaceutical research has changed.

258 easing attention in biological, medical, and biopharmaceutical research.

259 of oxidation in drug products containing the biopharmaceuticals Rituximab, Adalimumab, and Etanercept

260 To improve biopharmaceutical safety, we suggest transitioning their

261 pegfilgrastim batch was analyzed as a a real biopharmaceutical sample to confirm the feasibility of o

262 mance guidelines and applied to characterize biopharmaceutical samples, including IgG4 monoclonal ant

263 to detect low ppm levels of residual HCPs in biopharmaceutical samples.

264 mer's) but also due to its importance in the biopharmaceutical sector, where aggregation of protein t

265 ave application across both the chemical and biopharmaceutical sectors.

266 otide, and helps to overcome their intrinsic biopharmaceutical shortcomings, such as poor enzymatic s

267 xciting theoretical potential for converting biopharmaceutical strategies such gene correction and CR

268 timately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market.

269 ant determinant of efficacy and clearance of biopharmaceuticals such as immunoglobulin G (IgG).

270 the most common route of self-administering biopharmaceuticals such as proteins and peptides.

271 rization using TERS, which would have use in biopharmaceutical synthesis and formulation research.

272 demonstrate the utility of the HBD of NRG in biopharmaceutical targeting and provide a new way to blo

273 utilized to extend the serum persistence of biopharmaceuticals that are fused to albumin.

274 chnology for vaccines, therapeutics or other biopharmaceuticals that are not compatible with lyophili

275 s have emerged as a fast-growing category of biopharmaceuticals that have been widely applied in scie

276 ins (HCPs) are process-related impurities of biopharmaceuticals that remain at trace levels despite m

277 Biopharmaceuticals that target specific disease-mediatin

278 al of Chlamydomonas to produce a recombinant biopharmaceutical, the HIV antigen P24.

279 using a continuous process for production of biopharmaceuticals, the traditional bottom-up method, al

280 When used as biopharmaceutical therapeutics, such heterogeneities may

281 tions ranging from processing and storage of biopharmaceuticals to cryo-EM analysis of protein comple

282 There is a need to improve delivery of biopharmaceuticals to enable less-invasive delivery rout

283 hould have general use as fusion partners to biopharmaceuticals to extend their half-lives in vivo.

284 Noncovalent binding of biopharmaceuticals to human serum albumin protects again

285 p controlled-release systems for delivery of biopharmaceuticals to the eye.

286 se traditional pharmaceuticals as opposed to biopharmaceuticals to treat single-gene disorders.

287 Plastid-made biopharmaceuticals treat major metabolic or genetic diso

288 een used to prolong the in vivo half-life of biopharmaceuticals, using the interaction with FcRn to i

289 the workflow by cloning 24 human proteins of biopharmaceutical value, either as direct therapeutics o

290 he potential to enhance the oral delivery of biopharmaceuticals via a transient regulation of an endo

291 rinted polymers, offer an ideal platform for biopharmaceutical virus purification.

292 mprove the LC-MS characterization of protein biopharmaceuticals, which has the potential to be widely

293 recent advances in yeast-based expression of biopharmaceuticals will be discussed.

294 Moreover, HSA is a biopharmaceutical with a growing repertoire of putative

295 an interferon-beta1 (Avonex, rhIFN-beta1), a biopharmaceutical with complex glycosylation at a single

296 ing, purifying, and formulating a commercial biopharmaceutical with consistent therapeutic properties

297 dily supports large-scale glycan analysis of biopharmaceuticals with rapid deglycosylation times.

298 in biosensors), or as nonimmunogenic in vivo biopharmaceuticals with superior biodistribution and blo

299 a significant hurdle for the development of biopharmaceuticals with therapeutic effects within the c

300 ement allows for real-time monitoring of the biopharmaceutical within the injection chamber, and can